US Bancorp DE raised its stake in shares of GSK plc (NYSE:GSK - Free Report) by 12.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 236,770 shares of the pharmaceutical company's stock after purchasing an additional 25,781 shares during the quarter. US Bancorp DE's holdings in GSK were worth $9,679,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also bought and sold shares of GSK. Eastern Bank bought a new stake in GSK during the third quarter valued at approximately $26,000. Concord Wealth Partners lifted its holdings in shares of GSK by 231.8% in the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company's stock worth $32,000 after acquiring an additional 547 shares during the last quarter. Ashton Thomas Private Wealth LLC bought a new stake in shares of GSK in the 2nd quarter worth approximately $37,000. Fortitude Family Office LLC bought a new stake in shares of GSK in the 3rd quarter worth approximately $42,000. Finally, PrairieView Partners LLC bought a new stake in shares of GSK in the 2nd quarter worth approximately $47,000. 15.74% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of brokerages have recently weighed in on GSK. Guggenheim lowered shares of GSK from a "buy" rating to a "neutral" rating in a report on Thursday. Argus upgraded shares of GSK to a "strong-buy" rating in a report on Wednesday, August 7th. Barclays upgraded shares of GSK to a "hold" rating in a report on Tuesday, August 27th. Finally, UBS Group lowered shares of GSK from a "buy" rating to a "neutral" rating in a report on Monday, July 8th. Five analysts have rated the stock with a hold rating, one has issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $50.00.
Read Our Latest Stock Report on GSK
GSK Trading Up 0.3 %
GSK traded up $0.12 during trading on Friday, reaching $36.88. The company had a trading volume of 6,877,236 shares, compared to its average volume of 6,413,687. GSK plc has a 52 week low of $33.67 and a 52 week high of $45.92. The stock has a market cap of $76.44 billion, a P/E ratio of 23.95, a PEG ratio of 1.45 and a beta of 0.66. The company has a quick ratio of 0.54, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The business has a 50 day simple moving average of $40.66 and a 200-day simple moving average of $41.04.
GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings data on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.09. The company had revenue of $9.95 billion for the quarter, compared to analysts' expectations of $9.49 billion. GSK had a return on equity of 50.62% and a net margin of 7.97%. On average, equities analysts anticipate that GSK plc will post 3.45 EPS for the current fiscal year.
GSK Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be issued a dividend of $0.3928 per share. This represents a $1.57 annualized dividend and a dividend yield of 4.26%. The ex-dividend date is Friday, November 15th. This is a positive change from GSK's previous quarterly dividend of $0.38. GSK's dividend payout ratio is currently 100.00%.
Insider Activity
In related news, major shareholder Plc Gsk acquired 2,791,930 shares of GSK stock in a transaction on Friday, September 27th. The stock was acquired at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the purchase, the insider now owns 16,775,691 shares of the company's stock, valued at approximately $134,205,528. This represents a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 10.00% of the company's stock.
GSK Profile
(
Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
See Also
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
